Modelling lifelong effects of different prophylactic treatment strategies for severe haemophilia A-Reference-Cited by-同舟云学术

Modelling lifelong effects of different prophylactic treatment strategies for severe haemophilia A

Published:2016-06-28 Issue:5 Volume:22 Page:
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Fischer K.¹²,Lewandowski D.¹,Janssen M. P.¹³

Affiliation:

1. Julius Center for Health Sciences and Primary care University Medical Center Utrecht Utrecht The Netherlands

2. Van Creveldkliniek University Medical Center Utrecht Utrecht The Netherlands

3. Research Division Transfusion Technology Assessment Department Sanquin Blood Supply Foundation Amsterdam The Netherlands

Funder

ZonMw

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13019

Reference28 articles.

1. Haemophilia in Sweden VII. Incidence, treatment and prophylaxis of arthropathy and other musculo‐skeletal manifestations of haemophilia A and B;Ahlberg A;Acta Orthop Scand,1965

2. HAEMOPHILIA PROPHYLAXIS IN SWEDEN

3. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease

4. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France

5. Dose and response in haemophilia - optimization of factor replacement therapy

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe;Orphanet Journal of Rare Diseases;2021-12

2. Clinical, humanistic, and economic burden of severe hemophilia B in the United States: Results from the CHESS US and CHESS US+ population surveys;Orphanet Journal of Rare Diseases;2021-03-20

3. A cost-effectiveness analysis of the prophylaxis versus on-demand regimens in severe hemophilia A patients under 12 years old in southern Iran;Hematology;2021-01-01

4. Strategies for Individualized Dosing of Clotting Factor Concentrates and Desmopressin in Hemophilia A and B;Therapeutic Drug Monitoring;2019-04

5. Navigating Speed Bumps on the Innovation Highway in Hemophilia Therapeutics;HemaSphere;2018-10